glp-1 receptor agonist nephrolithiasis Nephroprotective effects of agonists: where do we stand? | Journal of Nephrology GLP-1 receptor agonists in patients

Description

There is controversy as to whether glucose-induced GLP-1 secretion is disturbed in patients with type-2 diabetes

administered GLP-1 depends on vagal afferents [692,694] and thus suggests a similar mechanism for i.p

doi: 10.2337/diab.42.5.658 95 ReedJBainSKanamarlapudiV

While lixisenatide is only available outside of the US, exenatide is commercially available twice daily in both Europe and the US

this difference may result from a ~5x stronger effect produced by GLP-1 analogs, compared to DPP-4 inhibitors (Charbonnel & Cariou, 2011) No change in weight Contraindications: type I diabetes (these patients lack pancreatic beta cells) diabetic ketoacidosis (it would not be effective for treating this condition) an association between DPP-4 inhibitors and heart failure has been observed for two members of this drug class in patients with type 2 DM and atherosclerosis